Converging roles of ion channels, calcium, metabolic stress, and activity pattern of Substantia nigra dopaminergic neurons in health and Parkinson's disease

Journal of Neurochemistry

Volumn , Issue , 2016, Pages 156-178

  Duda, Johanna ^a   Pötschke, Christina ^a   Liss, Birgit ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

A type Kv4.3 KChip3 potassium channels; ambroxol; Cav1.3 L type Cav3.1 T type calcium channels; D2 autoreceptor coupled GIRK2 channels; Kir6.2 SUR1 potassium channels; neuronal calcium sensor NCS 1

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM); CALCIUM; CALCIUM BINDING PROTEIN; ION CHANNEL; POTASSIUM ION; VOLTAGE GATED CALCIUM CHANNEL;

AGING; BASAL GANGLION; BRAIN REGION; CALCIUM CELL LEVEL; CALCIUM HOMEOSTASIS; CALCIUM TRANSPORT; CELL SURVIVAL; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; ELECTRIC ACTIVITY; EXOCYTOSIS; GBA GENE; GENE; GENE MUTATION; HUMAN; LYSOSOME; MESENCEPHALON; METABOLIC STRESS; MITOCHONDRION; NERVE CELL; NONHUMAN; PARK GENE; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; RISK FACTOR; SUBSTANTIA NIGRA;

EID: 84991202212     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.13572     Document Type: Review

References (364)

1. Adams P. J. and Snutch T. P. (2007) Calcium channelopathies: voltage-gated calcium channels. Subcell. Biochem. 45, 215–251.
2. Agid Y., Ruberg M., Javoy-Agid F. et al. (1993) Are dopaminergic neurons selectively vulnerable to Parkinson's disease? Adv. Neurol. 60, 148–164.
3. Aidi-Knani S., Regaya I., Amalric M. and Mourre C. (2015) Kv4 channel blockade reduces motor and neuropsychiatric symptoms in rodent models of Parkinson's disease. Behav. Pharmacol. 26, 91–100.
4. Albin R. L. and Dauer W. T. (2014) Magic shotgun for Parkinson's disease? Brain 137, 1274–1275.
5. Alexeyev M., Shokolenko I., Wilson G. and LeDoux S. (2013) The maintenance of mitochondrial DNA integrity–critical analysis and update. Cold Spring Harb Perspect. Biol. 5, a012641.
6. Ambrosi G., Cerri S. and Blandini F. (2014) A further update on the role of excitotoxicity in the pathogenesis of Parkinson's disease. J. Neural. Transm. (Vienna) 121, 849–859.
7. Ambrosi G., Ghezzi C., Zangaglia R., Levandis G., Pacchetti C. and Blandini F. (2015) Ambroxol-induced rescue of defective glucocerebrosidase is associated with increased LIMP-2 and saposin C levels in GBA1 mutant Parkinson's disease cells. Neurobiol. Dis. 82, 235–242.
8. An W. F., Bowlby M. R., Betty M. et al. (2000) Modulation of A-type potassium channels by a family of calcium sensors. Nature 403, 553–556.
9. Anderson D., Mehaffey W. H., Iftinca M., Rehak R., Engbers J. D., Hameed S., Zamponi G. W. and Turner R. W. (2010) Regulation of neuronal activity by Cav3-Kv4 channel signaling complexes. Nat. Neurosci. 13, 333–337.
10. de d'Anglemont Tassigny X., Pascual A. and Lopez-Barneo J. (2015) GDNF-based therapies, GDNF-producing interneurons, and trophic support of the dopaminergic nigrostriatal pathway. Implications for Parkinson's disease. Front. Neuroanat., 9, 10.
11. Armstrong C. M. and Matteson D. R. (1985) Two distinct populations of calcium channels in a clonal line of pituitary cells. Science 227, 65–67.
12. Ashcroft F. M. (2007) The Walter B. Cannon Physiology in Perspective Lecture, 2007. ATP-sensitive K+ channels and disease: from molecule to malady. Am. J. Physiol. Endocrinol. Metab. 293, E880–E889.
13. Ashcroft F. M. (2010) New uses for old drugs: neonatal diabetes and sulphonylureas. Cell Metab. 11, 179–181.
14. Ashcroft F. M. and Gribble F. M. (1998) Correlating structure and function in ATP-sensitive K+ channels. Trends Neurosci. 21, 288–294.
15. Ashcroft F. M. and Rorsman P. (2013) K(ATP) channels and islet hormone secretion: new insights and controversies. Nat. Rev. Endocrinol. 9, 660–669.
16. Ashcroft F. M., Harrison D. E. and Ashcroft S. J. (1984) Glucose induces closure of single potassium channels in isolated rat pancreatic beta-cells. Nature 312, 446–448.
17. Asselta R., Rimoldi V., Siri C. et al. (2014) Glucocerebrosidase mutations in primary parkinsonism. Parkinsonism Relat. Disord. 20, 1215–1220.
18. Aumann T. D., Gantois I., Egan K., Vais A., Tomas D., Drago J. and Horne M. K. (2008) SK channel function regulates the dopamine phenotype of neurons in the Substantia nigra pars compacta. Exp. Neurol. 213, 419–430.
19. Bakowski D., Nelson C. and Parekh A. B. (2012) Endoplasmic reticulum-mitochondria coupling: local Ca(2)(+) signalling with functional consequences. Pflugers Arch. 464, 27–32.
20. Baughman J. M., Perocchi F., Girgis H. S. et al. (2011) Integrative genomics identifies MCU as an essential component of the mitochondrial calcium uniporter. Nature 476, 341–345.
21. Bean B. P. (2007a) The action potential in mammalian central neurons. Nat. Rev. Neurosci. 8, 451–465.
22. Bean B. P. (2007b) Neurophysiology: stressful pacemaking. Nature 447, 1059–1060.
23. Beaulieu J. M., Espinoza S. and Gainetdinov R. R. (2015) Dopamine receptors - IUPHAR Review 13. Br. J. Pharmacol. 172, 1–23.
24. Becker C., Jick S. S. and Meier C. R. (2008) Use of antihypertensives and the risk of Parkinson disease. Neurology 70, 1438–1444.
25. Beier K. T., Steinberg E. E., DeLoach K. E. et al. (2015) Circuit architecture of VTA dopamine neurons revealed by systematic Input-output mapping. Cell 162, 622–634.
26. Beilina A. and Cookson M. R. (2015) Genes associated with Parkinson's disease: regulation of autophagy and beyond. J. Neurochem. 139 (Suppl. 1), 91–107.
27. Bender A., Krishnan K. J., Morris C. M. et al. (2006) High levels of mitochondrial DNA deletions in Substantia nigra neurons in aging and Parkinson disease. Nat. Genet. 38, 515–517.
28. Bendikov-Bar I., Maor G., Filocamo M. and Horowitz M. (2013) Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase. Blood Cells Mol. Dis. 50, 141–145.
29. Berman S. B. and Hastings T. G. (1999) Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson's disease. J. Neurochem. 73, 1127–1137.
30. Bezprozvanny I. and Mattson M. P. (2008) Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease. Trends Neurosci. 31, 454–463.
31. Bishop M. W., Chakraborty S., Matthews G. A., Dougalis A., Wood N. W., Festenstein R. and Ungless M. A. (2010) Hyperexcitable Substantia nigra dopamine neurons in PINK1- and HtrA2/Omi-deficient mice. J. Neurophysiol. 104, 3009–3020.
32. Bjorklund A. and Dunnett S. B. (2007) Dopamine neuron systems in the brain: an update. Trends Neurosci. 30, 194–202.
33. Blandini F. (2010) An update on the potential role of excitotoxicity in the pathogenesis of Parkinson's disease. Funct. Neurol. 25, 65–71.
34. Blesa J. and Przedborski S. (2014) Parkinson's disease: animal models and dopaminergic cell vulnerability. Front. Neuroanat. 8, 155.
35. Bolam J. P. and Pissadaki E. K. (2012) Living on the edge with too many mouths to feed: why dopamine neurons die. Mov. Disord. 27, 1478–1483.
36. Bond C. T., Maylie J. and Adelman J. P. (2005) SK channels in excitability, pacemaking and synaptic integration. Curr. Opin. Neurobiol. 15, 305–311.
37. Bonifati V., Rizzu P., van Baren M. J. et al. (2003) Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299, 256–259.
38. Borgkvist A., Mosharov E. V. and Sulzer D. (2014) Calcium currents regulate dopamine autoreceptors. Brain 137, 2113–2115.
39. Bourdenx M., Bezard E. and Dehay B. (2014) Lysosomes and alpha-synuclein form a dangerous duet leading to neuronal cell death. Front. Neuroanat. 8, 83.
40. Bourdy R. and Barrot M. (2012) A new control center for dopaminergic systems: pulling the VTA by the tail. Trends Neurosci. 35, 681–690.
41. Bozzi Y. and Borrelli E. (2006) Dopamine in neurotoxicity and neuroprotection: what do D2 receptors have to do with it? Trends Neurosci. 29, 167–174.
42. Braak H., Ghebremedhin E., Rub U., Bratzke H. and Del Tredici K. (2004) Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res. 318, 121–134.
43. Branch S. Y., Sharma R. and Beckstead M. J. (2014) Aging decreases L-type calcium channel currents and pacemaker firing fidelity in Substantia nigra dopamine neurons. J. Neurosci. 34, 9310–9318.
44. Brauer R., Bhaskaran K., Chaturvedi N., Dexter D. T., Smeeth L. and Douglas I. (2015) Glitazone Treatment and Incidence of Parkinson's Disease among People with Diabetes: A Retrospective Cohort Study. PLoS Med. 12(7), e1001854.
45. Brichta L. and Greengard P. (2014) Molecular determinants of selective dopaminergic vulnerability in Parkinson's disease: an update. Front. Neuroanat. 8, 152.
46. Brimblecombe K. R., Gracie C. J., Platt N. J. and Cragg S. J. (2015) Gating of dopamine transmission by calcium and axonal N-, Q-, T- and L-type voltage-gated calcium channels differs between striatal domains. J. Physiol. 593, 929–946.
47. Brini M. (2003) Ca(2 +) signalling in mitochondria: mechanism and role in physiology and pathology. Cell Calcium 34, 399–405.
48. Brini M., Cali T., Ottolini D. and Carafoli E. (2014) Neuronal calcium signaling: function and dysfunction. Cell. Mol. Life Sci. 71, 2787–2814.
49. Brisch R., Saniotis A., Wolf R. et al. (2014) The role of dopamine in schizophrenia from a neurobiological and evolutionary perspective: old fashioned, but still in vogue. Front. Psychiatry. 5, 47.
50. Bromberg-Martin E. S., Matsumoto M. and Hikosaka O. (2010) Dopamine in motivational control: rewarding, aversive, and alerting. Neuron 68, 815–834.
51. der van Brug M. P., Singleton A., Gasser T. and Lewis P. A. (2015) Parkinson's disease: from human genetics to clinical trials. Sci. Transl. Med. 7, 205, ps220.
52. Burgoyne R. D. and Haynes L. P. (2014) Sense and specificity in neuronal calcium signalling. Biochim. Biophys. Acta 1853, 1921–1932. doi:10.1016/j.bbamcr.2014.1010.1029.
53. Buxbaum J. D. (2004) A role for calsenilin and related proteins in multiple aspects of neuronal function. Biochem. Biophys. Res. Commun. 322, 1140–1144.
54. Cali T., Ottolini D., Negro A. and Brini M. (2012) alpha-Synuclein controls mitochondrial calcium homeostasis by enhancing endoplasmic reticulum-mitochondria interactions. J. Biol. Chem. 287, 17914–17929.
55. Cali T., Ottolini D. and Brini M. (2014) Calcium signaling in Parkinson's disease. Cell Tissue Res. 357, 439–454.
56. Catterall W. A. and Zheng N. (2015) Deciphering voltage-gated Na(+) and Ca(2 +) channels by studying prokaryotic ancestors. Trends Biochem. Sci. 40, 526–534.
57. Catterall W. A., Perez-Reyes E., Snutch T. P. and Striessnig J. (2005) International Union of Pharmacology. XLVIII. Nomenclature and structure-function relationships of voltage-gated calcium channels. Pharmacol. Rev. 57, 411–425.
58. Catterall W. A., Leal K. and Nanou E. (2013) Calcium channels and short-term synaptic plasticity. J. Biol. Chem. 288, 10742–10749.
59. Cens T., Rousset M., Leyris J. P., Fesquet P. and Charnet P. (2006) Voltage- and calcium-dependent inactivation in high voltage-gated Ca(2 +) channels. Prog. Biophys. Mol. Biol. 90, 104–117.
60. Cereda E., Barichella M., Cassani E., Caccialanza R. and Pezzoli G. (2012) Clinical features of Parkinson disease when onset of diabetes came first: A case-control study. Neurology. 78(19), 1507–1511.
61. Cereda E., Barichella M., Pedrolli C., Klersy C., Cassani E., Caccialanza R. and Pezzoli G. (2013) Diabetes and risk of Parkinson's disease. Mov. Disord. 28, 257.
62. Chan C. S., Guzman J. N., Ilijic E., Mercer J. N., Rick C., Tkatch T., Meredith G. E. and Surmeier D. J. (2007) ‘Rejuvenation’ protects neurons in mouse models of Parkinson's disease. Nature 447, 1081–1086.
63. Christel C. and Lee A. (2012) Ca2 + -dependent modulation of voltage-gated Ca2 + channels. Biochim. Biophys. Acta 1820, 1243–1252.
64. Christensen K. A., Myers J. T. and Swanson J. A. (2002) pH-dependent regulation of lysosomal calcium in macrophages. J. Cell Sci. 115, 599–607.
65. Ciron C., Zheng L., Bobela W., Knott G. W., Leone T. C., Kelly D. P. and Schneider B. L. (2015) PGC-1alpha activity in nigral dopamine neurons determines vulnerability to alpha-synuclein. Acta Neuropathol. Commun. 3, 16.
66. Clark R. and Proks P. (2010) ATP-sensitive potassium channels in health and disease. Adv. Exp. Med. Biol. 654, 165–192.
67. Coca A., Mazon P., Aranda P. et al. (2013) Role of dihydropyridinic calcium channel blockers in the management of hypertension. Expert Rev. Cardiovasc. Ther. 11, 91–105.
68. Collier T. J., Kanaan N. M. and Kordower J. H. (2011) Ageing as a primary risk factor for Parkinson's disease: evidence from studies of non-human primates. Nat. Rev. Neurosci. 12, 359–366.
69. Coskun P., Wyrembak J., Schriner S. E., Chen H. W., Marciniack C., Laferla F. and Wallace D. C. (2012) A mitochondrial etiology of Alzheimer and Parkinson disease. Biochim. Biophys. Acta 1820, 553–564.
70. Costa R. M. (2011) A selectionist account of de novo action learning. Curr. Opin. Neurobiol. 21, 579–586.
71. Coulson E. J., May L. M., Osborne S. L., Reid K., Underwood C. K., Meunier F. A., Bartlett P. F. and Sah P. (2008) p75 neurotrophin receptor mediates neuronal cell death by activating GIRK channels through phosphatidylinositol 4,5-bisphosphate. J. Neurosci. 28, 315–324.
72. Coyle J. T. (2003) Use it or lose it–do effortful mental activities protect against dementia? N. Engl. J. Med. 348, 2489–2490.
73. Crocker S. J., Smith P. D., Jackson-Lewis V. et al. (2003) Inhibition of calpains prevents neuronal and behavioral deficits in an MPTP mouse model of Parkinson's disease. J. Neurosci. 23, 4081–4091.
74. Dahlstrom A. and Fuxe K. (1964) Localization of monoamines in the lower brain stem. Experientia 20, 398–399.
75. Damier P., Hirsch E. C., Agid Y. and Graybiel A. M. (1999a) The Substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry. Brain, 122 (Pt 8), 1421–1436.
76. Damier P., Hirsch E. C., Agid Y. and Graybiel A. M. (1999b) The Substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain, 122 (Pt 8), 1437–1448.
77. D'Ardenne K., Eshel N., Luka J., Lenartowicz A., Nystrom L. E. and Cohen J. D. (2012) Role of prefrontal cortex and the midbrain dopamine system in working memory updating. Proc. Natl Acad. Sci. USA 109, 19900–19909.
78. De Mei C., Ramos M., Iitaka C. and Borrelli E. (2009) Getting specialized: presynaptic and postsynaptic dopamine D2 receptors. Curr. Opin. Pharmacol. 9, 53–58.
79. De Stefani D., Raffaello A., Teardo E., Szabo I. and Rizzuto R. (2011) A forty-kilodalton protein of the inner membrane is the mitochondrial calcium uniporter. Nature 476, 336–340.
80. Deacon R. M., Brook R. C., Meyer D., Haeckel O., Ashcroft F. M., Miki T., Seino S. and Liss B. (2006) Behavioral phenotyping of mice lacking the K ATP channel subunit Kir6.2. Physiol. Behav. 87, 723–733.
81. Dehay B., Martinez-Vicente M., Caldwell G. A., Caldwell K. A., Yue Z., Cookson M. R., Klein C., Vila M. and Bezard E. (2013) Lysosomal impairment in Parkinson's disease. Mov. Disord. 28, 725–732.
82. Deister C. A., Teagarden M. A., Wilson C. J. and Paladini C. A. (2009) An intrinsic neuronal oscillator underlies dopaminergic neuron bursting. J. Neurosci. 29, 15888–15897.
83. Del Tredici K. and Braak H. (2013) Dysfunction of the locus coeruleus-norepinephrine system and related circuitry in Parkinson's disease-related dementia. J. Neurol. Neurosurg. Psychiatry 84, 774–783.
84. Deleidi M. and Gasser T. (2013) The role of inflammation in sporadic and familial Parkinson's disease. Cell. Mol. Life Sci. 70, 4259–4273.
85. De-Miguel F. F. and Nicholls J. G. (2015) Release of chemical transmitters from cell bodies and dendrites of nerve cells. Philos. Trans. R. Soc. Lond. B Biol. Sci. 370(1672), pii: 20140181.
86. Di Fonzo A., Dekker M. C., Montagna P. et al. (2009) FBXO7 mutations cause autosomal recessive, early-onset parkinsonian-pyramidal syndrome. Neurology 72, 240–245.
87. Diepenbroek M., Casadei N., Esmer H. et al. (2014) Overexpression of the calpain-specific inhibitor calpastatin reduces human alpha-Synuclein processing, aggregation and synaptic impairment in [A30P]alphaSyn transgenic mice. Hum. Mol. Genet. 23, 3975–3989.
88. Dietrich A., Fahlbusch M. and Gudermann T. (2014) Classical transient receptor potential 1 (TRPC1): channel or channel regulator? Cells 3, 939–962.
89. Dolmetsch R. (2003) Excitation-transcription coupling: signaling by ion channels to the nucleus. Sci STKE, 2003, 166, PE4.
90. Dolmetsch R. E., Pajvani U., Fife K., Spotts J. M. and Greenberg M. E. (2001) Signaling to the nucleus by an L-type calcium channel - Calmodulin complex through the MAP kinase pathway. Science 294, 333–339.
91. Dopeso-Reyes I. G., Rico A. J., Roda E., Sierra S., Pignataro D., Lanz M., Sucunza D., Chang-Azancot L. and Lanciego J. L. (2014) Calbindin content and differential vulnerability of midbrain efferent dopaminergic neurons in macaques. Front. Neuroanat. 8, 146.
92. Dragicevic E., Poetschke C., Duda J. et al. (2014) Cav1.3 channels control D2-autoreceptor responses via NCS-1 in Substantia nigra dopamine neurons. Brain 137(8), 2287–2302.
93. Dragicevic E., Schiemann J. and Liss B. (2015) Dopamine midbrain neurons in health and Parkinson's disease: emerging roles of voltage-gated calcium channels and ATP-sensitive potassium channels. Neuroscience 284C, 798–814.
94. Drago I., Pizzo P. and Pozzan T. (2011) After half a century mitochondrial calcium in- and efflux machineries reveal themselves. EMBO J. 30, 4119–4125.
95. Drion G., Massotte L., Sepulchre R. and Seutin V. (2011) How modeling can reconcile apparently discrepant experimental results: the case of pacemaking in dopaminergic neurons. PLoS Comput. Biol. 7, e1002050.
96. Dryanovski D. I., Guzman J. N., Xie Z., Galteri D. J., Volpicelli-Daley L. A., Lee V. M., Miller R. J., Schumacker P. T. and Surmeier D. J. (2013) Calcium entry and alpha-synuclein inclusions elevate dendritic mitochondrial oxidant stress in dopaminergic neurons. J. Neurosci. 33, 10154–10164.
97. Dufty B. M., Warner L. R., Hou S. T. et al. (2007) Calpain-cleavage of alpha-synuclein: connecting proteolytic processing to disease-linked aggregation. Am. J. Pathol. 170, 1725–1738.
98. Durante P., Cardenas C. G., Whittaker J. A., Kitai S. T. and Scroggs R. S. (2004) Low-threshold L-type calcium channels in rat dopamine neurons. J Neurophysiol. 91, 1450–1454.
99. Epstein B. J., Vogel K. and Palmer B. F. (2007) Dihydropyridine calcium channel antagonists in the management of hypertension. Drugs 67, 1309–1327.
100. Fearnley J. M. and Lees A. J. (1991) Ageing and Parkinson's disease: Substantia nigra regional selectivity. Brain 114(Pt 5), 2283–2301.
101. Flagg T. P., Enkvetchakul D., Koster J. C. and Nichols C. G. (2010) Muscle KATP channels: recent insights to energy sensing and myoprotection. Physiol. Rev. 90, 799–829.
102. Flockerzi V., Bosse E., Biel M., Hullin R. and Hofmann F. (1991) High voltage activated calcium channels: molecular composition and function. Eur. Heart J. 12, 95–98.
103. Fois G., Hobi N., Felder E., Ziegler A., Miklavc P., Walther P., Radermacher P., Haller T. and Dietl P. (2015) A new role for an old drug: ambroxol triggers lysosomal exocytosis via pH-dependent Ca(2 +) release from acidic Ca(2 +) stores. Cell Calcium 58, 628–637.
104. Ford C. P. (2014) The role of D2-autoreceptors in regulating dopamine neuron activity and transmission. Neuroscience 282, 13–22.
105. Ford C. P., Gantz S. C., Phillips P. E. and Williams J. T. (2010) Control of extracellular dopamine at dendrite and axon terminals. J. Neurosci. 30, 6975–6983.
106. Franz O., Liss B., Neu A. and Roeper J. (2000) Single-cell mRNA expression of HCN1 correlates with a fast gating phenotype of hyperpolarization-activated cyclic nucleotide-gated ion channels (Ih) in central neurons. Eur. J. Neurosci. 12, 2685–2693.
107. Funayama M., Hasegawa K., Kowa H., Saito M., Tsuji S. and Obata F. (2002) A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1. Ann. Neurol. 51, 296–301.
108. Games D., Valera E., Spencer B. et al. (2014) Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models. J. Neurosci. 34, 9441–9454.
109. Gan-Or Z., Dion P. A. and Rouleau G. A. (2015) Genetic perspective on the role of the autophagy-lysosome pathway in Parkinson disease. Autophagy 11, 1443–1457.
110. Gasser T., Hardy J. and Mizuno Y. (2011) Milestones in PD genetics. Mov. Disord. 26, 1042–1048.
111. Gerfen C. R. and Surmeier D. J. (2011) Modulation of striatal projection systems by dopamine. Annu. Rev. Neurosci. 34, 441–466.
112. Gleichmann M. and Mattson M. P. (2011) Neuronal calcium homeostasis and dysregulation. Antioxid. Redox Signal. 14, 1261–1273.
113. Goedert M., Spillantini M. G., Del Tredici K. and Braak H. (2013) 100 years of Lewy pathology. Nat. Rev. Neurol. 9, 13–24.
114. Goldberg M. S., Pisani A., Haburcak M. et al. (2005) Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial Parkinsonism-linked gene DJ-1. Neuron 45, 489–496.
115. Gomez-Ospina N., Tsuruta F., Barreto-Chang O., Hu L. and Dolmetsch R. (2006) The C terminus of the L-type voltage-gated calcium channel Ca(V)1.2 encodes a transcription factor. Cell 127, 591–606.
116. Gomez-Suaga P., Churchill G. C., Patel S. and Hilfiker S. (2012) A link between LRRK2, autophagy and NAADP-mediated endolysosomal calcium signalling. Biochem. Soc. Trans. 40, 1140–1146.
117. Gonzalez-Hernandez T., Cruz-Muros I., Afonso-Oramas D., Salas-Hernandez J. and Castro-Hernandez J. (2010) Vulnerability of mesostriatal dopaminergic neurons in Parkinson's disease. Front. Neuroanat. 4, 140.
118. Grace A. A. and Bunney B. S. (1984a) The control of firing pattern in nigral dopamine neurons: burst firing. J. Neurosci. 4, 2877–2890.
119. Grace A. A. and Bunney B. S. (1984b) The control of firing pattern in nigral dopamine neurons: single spike firing. J. Neurosci. 4, 2866–2876.
120. Grace A. A. and Onn S. P. (1989) Morphology and electrophysiological properties of immunocytochemically identified rat dopamine neurons recorded in vitro. J. Neurosci. 9, 3463–3481.
121. Graef I. A., Mermelstein P. G., Stankunas K., Neilson J. R., Deisseroth K., Tsien R. W. and Crabtree G. R. (1999) L-type calcium channels and GSK-3 regulate the activity of NF-ATc4 in hippocampal neurons. Nature 401, 703–708.
122. Greene J. G. (2014) Causes and consequences of degeneration of the dorsal motor nucleus of the vagus nerve in Parkinson's disease. Antioxid. Redox Signal. 21, 649–667.
123. Grillner P. and Mercuri N. B. (2002) Intrinsic membrane properties and synaptic inputs regulating the firing activity of the dopamine neurons. Behav. Brain Res. 130, 149–169.
124. Guardia-Laguarta C., Area-Gomez E., Schon E. A. and Przedborski S. (2015) A new role for alpha-synuclein in Parkinson's disease: alteration of ER-mitochondrial communication. Mov. Disord. 30, 1026–1033.
125. Gudala K., Kanukula R. and Bansal D. (2015) Reduced Risk of Parkinson's Disease in Users of Calcium Channel Blockers: A Meta-Analysis. Int J Chronic Dis 2015, 697404.
126. Gueguinou M., Chantome A., Fromont G., Bougnoux P., Vandier C. and Potier-Cartereau M. (2014) KCa and Ca(2 +) channels: the complex thought. Biochim. Biophys. Acta 1843, 2322–2333.
127. Guerreiro S., Florence C., Rousseau E., Hamadat S., Hirsch E. C. and Michel P. P. (2015) The sleep-modulating peptide orexin-B protects midbrain dopamine neurons from degeneration, alone or in cooperation with nicotine. Mol. Pharmacol. 87, 525–532.
128. Guzman J. N., Sanchez-Padilla J., Chan C. S. and Surmeier D. J. (2009) Robust pacemaking in Substantia nigra dopaminergic neurons. J. Neurosci. 29, 11011–11019.
129. Guzman J. N., Sanchez-Padilla J., Wokosin D., Kondapalli J., Ilijic E., Schumacker P. T. and Surmeier D. J. (2010) Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1. Nature 468, 696–700.
130. Hage T. A. and Khaliq Z. M. (2015) Tonic firing rate controls dendritic Ca2 + signaling and synaptic gain in Substantia nigra dopamine neurons. J. Neurosci. 35, 5823–5836.
131. Hahn J., Tse T. E. and Levitan E. S. (2003) Long-term K+ channel-mediated dampening of dopamine neuron excitability by the antipsychotic drug haloperidol. J Neurosci. 23, 10859–10866.
132. Hajnoczky G., Booth D., Csordas G. et al. (2014) Reliance of ER-mitochondrial calcium signaling on mitochondrial EF-hand Ca binding proteins: miros, MICUs, LETM1 and solute carriers. Curr. Opin. Cell Biol. 29C, 133–141.
133. Hao L. Y., Giasson B. I. and Bonini N. M. (2010) DJ-1 is critical for mitochondrial function and rescues PINK1 loss of function. Proc. Natl Acad. Sci. USA 107, 9747–9752.
134. Hardy J. (2010) Genetic analysis of pathways to Parkinson disease. Neuron 68, 201–206.
135. Heinzen E. L., Arzimanoglou A., Brashear A. et al. (2014) Distinct neurological disorders with ATP1A3 mutations. Lancet. Neurol. 13, 503–514.
136. Henchcliffe C. and Beal M. F. (2008) Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat. Clin. Pract. Neurol. 4, 600–609.
137. Henny P., Brown M. T., Northrop A., Faunes M., Ungless M. A., Magill P. J. and Bolam J. P. (2012) Structural correlates of heterogeneous in vivo activity of midbrain dopaminergic neurons. Nat. Neurosci. 15, 613–619.
138. Hindle J. V. (2010) Ageing, neurodegeneration and Parkinson's disease. Age Ageing 39, 156–161.
139. Hirsch E. C. and Hunot S. (2009) Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol. 8, 382–397.
140. Hirsch E., Graybiel A. M. and Agid Y. A. (1988) Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 334, 345–348.
141. Hofmann F., Flockerzi V., Kahl S. and Wegener J. W. (2014) L-type CaV1.2 calcium channels: from in vitro findings to in vivo function. Physiol. Rev. 94, 303–326.
142. Hoglinger G. U., Alvarez-Fischer D., Arias-Carrion O. et al. (2015) A new dopaminergic nigro-olfactory projection. Acta Neuropathol. 130, 333–348.
143. Hopp S. C., Royer S. E., D'Angelo H. M., Kaercher R. M., Fisher D. A. and Wenk G. L. (2015) Differential neuroprotective and anti-inflammatory effects of L-type voltage dependent calcium channel and ryanodine receptor antagonists in the Substantia nigra and locus coeruleus. J. Neuroimmune Pharmacol. 10, 35–44.
144. Hoppins S. and Nunnari J. (2012) Cell Biology. Mitochondrial dynamics and apoptosis–the ER connection. Science 337, 1052–1054.
145. Howarth C., Gleeson P. and Attwell D. (2012) Updated energy budgets for neural computation in the neocortex and cerebellum. J. Cereb. Blood Flow Metab. 32, 1222–1232.
146. Hu G., Jousilahti P., Bidel S., Antikainen R. and Tuomilehto J. (2007) Type 2 diabetes and the risk of Parkinson's disease. Diabetes Care 30, 842–847.
147. Huang H., Ng C. Y., Yu D., Zhai J., Lam Y. and Soong T. W. (2014) Modest CaV1.342-selective inhibition by compound 8 is beta-subunit dependent. Nat. Commun., 5, 4481.
148. Hunn B. H., Cragg S. J., Bolam J. P., Spillantini M. G. and Wade-Martins R. (2015) Impaired intracellular trafficking defines early Parkinson's disease. Trends Neurosci. 38, 178–188.
149. Jackson-Lewis V. and Przedborski S. (2007) Protocol for the MPTP mouse model of Parkinson's disease. Nat. Protoc. 2, 141–151.
150. Janezic S., Threlfell S., Dodson P. D. et al. (2013) Deficits in dopaminergic transmission precede neuron loss and dysfunction in a new Parkinson model. Proc. Natl Acad. Sci. USA 110, E4016–E4025.
151. Jang M., Jang J. Y., Kim S. H., Uhm K. B., Kang Y. K., Kim H. J., Chung S. and Park M. K. (2011) Functional organization of dendritic Ca2 + signals in midbrain dopamine neurons. Cell Calcium 50, 370–380.
152. Jellinger K. A. (1991) Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway. Mol. Chem. Neuropathol. 14, 153–197.
153. Jerng H. H. and Pfaffinger P. J. (2014) Modulatory mechanisms and multiple functions of somatodendritic A-type K (+) channel auxiliary subunits. Front Cell Neurosci. 8, 82.
154. Jhou T. C., Good C. H., Rowley C. S., Xu S. P., Wang H., Burnham N. W., Hoffman A. F., Lupica C. R. and Ikemoto S. (2013) Cocaine drives aversive conditioning via delayed activation of dopamine-responsive habenular and midbrain pathways. J. Neurosci. 33, 7501–7512.
155. Jin X. and Costa R. M. (2010) Start/stop signals emerge in nigrostriatal circuits during sequence learning. Nature 466, 457–462.
156. Jo D. G., Kim M. J., Choi Y. H., Kim I. K., Song Y. H., Woo H. N., Chung C. W. and Jung Y. K. (2001) Pro-apoptotic function of calsenilin/DREAM/KChIP3. FASEB J. 15, 589–591.
157. Johar K., Priya A. and Wong-Riley M. T. (2014) Regulation of Na(+)/K(+)-ATPase by neuron-specific transcription factor Sp4: implication in the tight coupling of energy production, neuronal activity and energy consumption in neurons. Eur. J. Neurosci. 39, 566–578.
158. Johnson S. W. and Wu Y. N. (2004) Multiple mechanisms underlie burst firing in rat midbrain dopamine neurons in vitro. Brain Res. 1019, 293–296.
159. Johnson S. W., Seutin V. and North R. A. (1992) Burst firing in dopamine neurons induced by N-methyl-D-aspartate: role of electrogenic sodium pump. Science 258, 665–667.
160. Kabbani N., Woll M. P., Nordman J. C. and Levenson R. (2012) Dopamine receptor interacting proteins: targeting neuronal calcium sensor-1/D2 dopamine receptor interaction for antipsychotic drug development. Curr. Drug Targets 13, 72–79.
161. Kalia L. V. and Lang A. E. (2015) Parkinson's disease. Lancet 386, 896–912.
162. Kang S., Cooper G., Dunne S. F., Dusel B., Luan C. H., Surmeier D. J. and Silverman R. B. (2012) CaV1.3-selective L-type calcium channel antagonists as potential new therapeutics for Parkinson's disease. Nat. Commun., 3, 1146.
163. Kang S., Cooper G., Dunne S. F., Luan C. H., Surmeier D. J. and Silverman R. B. (2013) Structure-activity relationship of N, N’-disubstituted pyrimidinetriones as Ca(V)1.3 calcium channel-selective antagonists for Parkinson's disease. J. Med. Chem. 56, 4786–4797.
164. Khaliq Z. M. and Bean B. P. (2010) Pacemaking in dopaminergic ventral tegmental area neurons: depolarizing drive from background and voltage-dependent sodium conductances. J. Neurosci. 30, 7401–7413.
165. Khan N. L., Jain S., Lynch J. M. et al. (2005) Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. Brain 128, 2786–2796.
166. Kieburtz K. and Wunderle K. B. (2013) Parkinson's disease: evidence for environmental risk factors. Mov. Disord. 28, 8–13.
167. Kilpatrick B. S., Magalhaes J., Beavan M. S. et al. (2015) Endoplasmic reticulum and lysosomal Ca2 + stores are remodelled in GBA1–linked Parkinson disease patient fibroblasts. Cell Calcium 1, 12–20.
168. Kimm T. and Bean B. P. (2014) Inhibition of A-type potassium current by the peptide toxin SNX-482. J Neurosci. 34, 9182–9189.
169. Kimm T., Khaliq Z. M. and Bean B. P. (2015) Differential regulation of action potential shape and burst-frequency firing by BK and Kv2 channels in Substantia nigra dopaminergic neurons. J. Neurosci. 35, 16404–16417.
170. Kirkwood T. B. and Austad S. N. (2000) Why do we age? Nature 408, 233–238.
171. Kitada T., Asakawa S., Hattori N., Matsumine H., Yamamura Y., Minoshima S., Yokochi M., Mizuno Y. and Shimizu N. (1998) Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392, 605–608.
172. Kordower J. H., Olanow C. W., Dodiya H. B., Chu Y., Beach T. G., Adler C. H., Halliday G. M. and Bartus R. T. (2013) Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain 136, 2419–2431.
173. V1.3) subunits can form l-type Ca2 + channels activating at negative voltages. J. Biol. Chem. 276, 22100–22106.
174. Koyama S., Jin Y. H. and Akaike N. (1999) ATP-sensitive and Ca2 + -activated K+ channel activities in the rat locus coeruleus neurons during metabolic inhibition. Brain Res. 828, 189–192.
175. Kramer E. R. and Liss B. (2015) Mechanisms of development and maintenance of dopaminergic neurons; in press. FEBS Lett. 589, 3760–3772.
176. Kraytsberg Y., Kudryavtseva E., McKee A. C., Geula C., Kowall N. W. and Khrapko K. (2006) Mitochondrial DNA deletions are abundant and cause functional impairment in aged human Substantia nigra neurons. Nat. Genet. 38, 518–520.
177. Kruger R., Sharma M., Riess O. et al. (2011) A large-scale genetic association study to evaluate the contribution of Omi/HtrA2 (PARK13) to Parkinson's disease. Neurobiol. Aging 32, 548, e549–518.
178. Laguna A., Schintu N., Nobre A. et al. (2015) Dopaminergic control of autophagic-lysosomal function implicates Lmx1b in Parkinson's disease. Nat. Neurosci. 18, 826–835.
179. Lahmann C., Kramer H. B. and Ashcroft F. M. (2015) Systemic administration of glibenclamide fails to achieve therapeutic levels in the brain and cerebrospinal fluid of rodents. PLoS ONE 10, e0134476.
180. Lambeth J. D. (2007) Nox enzymes, ROS, and chronic disease: an example of antagonistic pleiotropy. Free Radic. Biol. Med. 43, 332–347.
181. Lammel S., Hetzel A., Hackel O., Jones I., Liss B. and Roeper J. (2008) Unique properties of mesoprefrontal neurons within a dual mesocorticolimbic dopamine system. Neuron 57, 760–773.
182. Lammel S., Lim B. K., Ran C., Huang K. W., Betley M. J., Tye K. M., Deisseroth K. and Malenka R. C. (2012) Input-specific control of reward and aversion in the ventral tegmental area. Nature 491, 212–217.
183. Lang Y., Gong D., Fan Y. (2015) Pharmacoepidemiol Drug Saf. Calcium channel blocker use and risk of Parkinson's disease: a meta-analysis. 4, 559–566.
184. Langston J. W. and Ballard P. A., Jr (1983) Parkinson's disease in a chemist working with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. N. Engl. J. Med. 309, 310.
185. Laughlin S. B., van de Ruyter Steveninck R. R. and Anderson J. C. (1998) The metabolic cost of neural information. Nat. Neurosci. 1, 36–41.
186. Lee C. R. and Tepper J. M. (2009) Basal ganglia control of Substantia nigra dopaminergic neurons. J. Neural. Transm. Suppl. 73, 71–90.
187. Lefer D. J., Nichols C. G. and Coetzee W. A. (2009) Sulfonylurea receptor 1 subunits of ATP-sensitive potassium channels and myocardial ischemia/reperfusion injury. Trends Cardiovasc. Med. 19, 61–67.
188. Lehericy S., Bardinet E., Poupon C., Vidailhet M. and Francois C. (2014) 7 Tesla magnetic resonance imaging: a closer look at Substantia nigra anatomy in Parkinson's disease. Mov. Disord. 29, 1574–1581.
189. Lerner T. N., Shilyansky C., Davidson T. J. et al. (2015) Intact-brain analyses reveal distinct information carried by SNc dopamine subcircuits. Cell 162, 635–647.
190. Li M. and Adelman J. P. (2000) ChIPping away at potassium channel regulation. Nat. Neurosci. 3, 202–204.
191. Liang C. L., Wang T. T., Luby-Phelps K. and German D. C. (2007) Mitochondria mass is low in mouse Substantia nigra dopamine neurons: implications for Parkinson's disease. Exp. Neurol. 203, 370–380.
192. Lieb A., Ortner N. and Striessnig J. (2014) C-terminal modulatory domain controls coupling of voltage-sensing to pore opening in Cav1.3 L-type Ca(2 +) channels. Biophys. J. 106, 1467–1475.
193. Lima M. M., Targa A. D., Noseda A. C., Rodrigues L. S., Delattre A. M., dos Santos F. V., Fortes M. H., Maturana M. J. and Ferraz A. C. (2014) Does Parkinson's disease and type-2 diabetes mellitus present common pathophysiological mechanisms and treatments? CNS Neurol. Disord. Drug Targets 13, 418–428.
194. Lipscombe D., Helton T. D. and Xu W. (2004) L-type calcium channels: the low down. J. Neurophysiol. 92, 2633–2641.
195. Lipscombe D., Allen S. E. and Toro C. P. (2013) Control of neuronal voltage-gated calcium ion channels from RNA to protein. Trends Neurosci. 36, 598–609.
196. Liss B. and Roeper J. (2001) Molecular physiology of neuronal K-ATP channels (review). Mol. Membr. Biol. 18, 117–127.
197. Liss B. and Roeper J. (2010) Ion channels and regulation of dopamine neuron activity in Dopamine handbook (Leslie S. D. I., Iversen L., Dunnett S. B. and Björklund A. eds), pp. 118–138. Oxford, University press.
198. Liss B., Bruns R. and Roeper J. (1999a) Alternative sulfonylurea receptor expression defines metabolic sensitivity of K-ATP channels in dopaminergic midbrain neurons. EMBO J. 18, 833–846.
199. Liss B., Neu A. and Roeper J. (1999b) The weaver mouse gain-of-function phenotype of dopaminergic midbrain neurons is determined by coactivation of wvGirk2 and K-ATP channels. J. Neurosci. 19, 8839–8848.
200. Liss B., Franz O., Sewing S., Bruns R., Neuhoff H. and Roeper J. (2001) Tuning pacemaker frequency of individual dopaminergic neurons by Kv4.3L and KChip3.1 transcription. EMBO J. 20, 5715–5724.
201. Liss B., An W. F. and Roeper J. (2002) Differential co-expression of KChip subunits defines inactivation kinetics of A-type potassium channels in dopaminergic VTA neurons. 32th annual SFN meeing, Abstr. 438.17.
202. Liss B., Haeckel O., Wildmann J., Miki T., Seino S. and Roeper J. (2005) K-ATP channels promote the differential degeneration of dopaminergic midbrain neurons. Nat. Neurosci. 8, 1742–1751.
203. Lu L., Fu D. L., Li H. Q., Liu A. J., Li J. H. and Zheng G. Q. (2014) Diabetes and risk of Parkinson's disease: an updated meta-analysis of case-control studies. PLoS ONE 9, e85781.
204. Lu L., Sirish P., Zhang Z. et al. (2015) Regulation of gene transcription by voltage-gated L-type calcium channel, Cav1.3. J. Biol. Chem. 290, 4663–4676.
205. Luscher C. and Slesinger P. A. (2010) Emerging roles for G protein-gated inwardly rectifying potassium (GIRK) channels in health and disease. Nat. Rev. Neurosci. 11, 301–315.
206. Maegawa G. H., Tropak M. B., Buttner J. D. et al. (2009) Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease. J. Biol. Chem. 284, 23502–23516.
207. Majewski L. and Kuznicki J. (2015) SOCE in neurons: Signaling or just refilling? Biochim. Biophys. Acta 1853, 1940–1952.
208. Malli R., Frieden M., Osibow K., Zoratti C., Mayer M., Demaurex N. and Graier W. F. (2003) Sustained Ca2 + transfer across mitochondria is Essential for mitochondrial Ca2 + buffering, sore-operated Ca2 + entry, and Ca2 + store refilling. J. Biol. Chem. 278, 44769–44779.
209. Mandel G. and Goodman R. H. (1999) Cell signalling. DREAM on without calcium. Nature 398, 29–30.
210. Mao Z., Bonni A., Xia F., Nadal-Vicens M. and Greenberg M. E. (1999) Neuronal activity-dependent cell survival mediated by transcription factor MEF2. Science 286, 785–790.
211. Margolis E. B., Coker A. R., Driscoll J. R., Lemaitre A. I. and Fields H. L. (2010) Reliability in the identification of midbrain dopamine neurons. PLoS ONE 5, e15222.
212. Marras C., Gruneir A., Rochon P., Wang X., Anderson G., Brotchie J., Bell C. M., Fox S. and Austin P. C. (2012) Dihydropyridine calcium channel blockers and the progression of parkinsonism. Ann. Neurol. 71, 362–369.
213. Martin L. J., Semenkow S., Hanaford A. and Wong M. (2014) Mitochondrial permeability transition pore regulates Parkinson's disease development in mutant alpha-synuclein transgenic mice. Neurobiol. Aging 35, 1132–1152.
214. Matschke L. A., Bertoune M., Roeper J., Snutch T. P., Oertel W. H., Rinne S. and Decher N. (2015) A concerted action of L- and T-type Ca(2 +) channels regulates locus coeruleus pacemaking. Mol. Cell Neurosci. 68, 293–302.
215. Mazzulli J. R., Xu Y. H., Sun Y., Knight A. L., McLean P. J., Caldwell G. A., Sidransky E., Grabowski G. A. and Krainc D. (2011) Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 146, 37–52.
216. McNeill A., Magalhaes J., Shen C. et al. (2014) Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells. Brain 137, 1481–1495.
217. McTaggart J. S., Clark R. H. and Ashcroft F. M. (2010) The role of the KATP channel in glucose homeostasis in health and disease: more than meets the islet. J. Physiol. 588, 3201–3209.
218. Mellstrom B., Sahun I., Ruiz-Nuno A. et al. (2014) DREAM controls the on/off switch of specific activity-dependent transcription pathways. Mol. Cell. Biol. 34, 877–887.
219. Mercuri N. B., Bonci A., Calabresi P., Stratta F., Stefani A. and Bernardi G. (1994) Effects of dihydropyridine calcium antagonists on rat midbrain dopaminergic neurones. Br. J. Pharmacol. 113, 831–838.
220. Meredith G. E. and Rademacher D. J. (2011) MPTP mouse models of Parkinson's disease: an update. J. Parkinsons Dis. 1, 19–33.
221. Michel P. P., Alvarez-Fischer D., Guerreiro S., Hild A., Hartmann A. and Hirsch E. C. (2007) Role of activity-dependent mechanisms in the control of dopaminergic neuron survival. J. Neurochem. 101, 289–297.
222. Michel P. P., Toulorge D., Guerreiro S. and Hirsch E. C. (2013) Specific needs of dopamine neurons for stimulation in order to survive: implication for Parkinson disease. FASEB J. 27, 3414–3423.
223. Miki T. and Seino S. (2005) Roles of KATP channels as metabolic sensors in acute metabolic changes. J. Mol. Cell. Cardiol. 38, 917–925.
224. Miki T., Liss B., Minami K. et al. (2001) ATP-sensitive K+ channels in the hypothalamus are essential for the maintenance of glucose homeostasis. Nat. Neurosci. 4, 507–512.
225. Minami K., Miki T., Kadowaki T. and Seino S. (2004) Roles of ATP-sensitive K+ channels as metabolic sensors: studies of Kir6.x null mice. Diabetes, 53 Suppl 3, S176–S180.
226. Miura T. and Miki T. (2003) ATP-sensitive K+ channel openers: old drugs with new clinical benefits for the heart. Curr. Vasc. Pharmacol. 1, 251–258.
227. Murphy M. P. (2009) How mitochondria produce reactive oxygen species. Biochem. J. 417, 1–13.
228. Nam Y. J., da Lee H., Lee M. S. and Lee C. S. (2015) K(ATP) channel block prevents proteasome inhibitor-induced apoptosis in differentiated PC12 cells. Eur. J. Pharmacol. 764, 582–591.
229. Navarro B., Kennedy M. E., Velimirovic B., Bhat D., Peterson A. S. and Clapham D. E. (1996) Nonselective and G betagamma-insensitive weaver K+ channels. Science 272, 1950–1953.
230. Nedergaard S., Flatman J. A. and Engberg I. (1993) Nifedipine- and omega-conotoxin-sensitive Ca2 + conductances in guinea-pig Substantia nigra pars compacta neurones. J. Physiol. 466, 727–747.
231. Neuhoff H., Neu A., Liss B. and Roeper J. (2002) I(h) channels contribute to the different functional properties of identified dopaminergic subpopulations in the midbrain. J. Neurosci. 22, 1290–1302.
232. Ng E., Varaschin R. K., Su P., Browne C. J., Hermainski J., Le Foll B., Pongs O., Liu F., Trudeau L. E., Roder J.C. and Wong A. H. (2016) Neuronal calcium sensor-1 deletion in the mouse decreases motivation and dopamine release in the nucleus accumbens. Behav Brain Res. 301, 213–225.
233. Nichols C. G. (2006) KATP channels as molecular sensors of cellular metabolism. Nature 440, 470–476.
234. Obeso J. A. and Lanciego J. L. (2011) Past, present, and future of the pathophysiological model of the Basal Ganglia. Front. Neuroanat. 5, 39.
235. de Oliveira R. B., Howlett M. C., Gravina F. S., Imtiaz M. S., Callister R. J., Brichta A. M. and van Helden D. F. (2010) Pacemaker currents in mouse locus coeruleus neurons. Neuroscience 170, 166–177.
236. V1.3 L-type Ca2 + channels is dependent on a Shank-binding domain. J. Neurosci. 25, 1050–1062.
237. Oo T. F., Blazeski R., Harrison S. M., Henchcliffe C., Mason C. A., Roffler-Tarlov S. K. and Burke R. E. (1996) Neuron death in the Substantia nigra of weaver mouse occurs late in development and is not apoptotic. J. Neurosci. 16, 6134–6145.
238. Ortner N. J., Bock G., Vandael D. H., Mauersberger R., Draheim H. J., Gust R., Carbone E., Tuluc P. and Striessnig J. (2014) Pyrimidine-2,4,6-triones are a new class of voltage-gated L-type Ca2 + channel activators. Nat. Commun. 5, 3897.
239. Osawa M., Tong K. I., Lilliehook C., Wasco W., Buxbaum J. D., Cheng H. Y., Penninger J. M., Ikura M. and Ames J. B. (2001) Calcium-regulated DNA binding and oligomerization of the neuronal calcium-sensing protein, calsenilin/DREAM/KChIP3. J. Biol. Chem. 276, 41005–41013.
240. Osborne P. B., Halliday G. M., Cooper H. M. and Keast J. R. (2005) Localization of immunoreactivity for deleted in colorectal cancer (DCC), the receptor for the guidance factor netrin-1, in ventral tier dopamine projection pathways in adult rodents. Neuroscience 131, 671–681.
241. Osellame L. D. and Duchen M. R. (2014) Quality control gone wrong: mitochondria, lysosomal storage disorders and neurodegeneration. Br. J. Pharmacol. 171, 1958–1972.
242. Pacelli C., Giguere N., Bourque M. J., Levesque M., Slack R. S. and Trudeau L. E. (2015) Elevated Mitochondrial Bioenergetics and Axonal Arborization Size Are Key Contributors to the Vulnerability of Dopamine Neurons. Curr. Biol. 25, 2349–2360.
243. Paladini C. A. and Roeper J. (2014) Generating bursts (and pauses) in the dopamine midbrain neurons. Neuroscience 282C, 109–121.
244. Parkinson Study, G (2013) Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD). Mov. Disord. 28, 1823–1831.
245. Parsons P. A. (2007) Antagonistic pleiotropy and the stress theory of aging. Biogerontology 8, 613–617.
246. Pasternak B., Svanstrom H., Nielsen N. M., Fugger L., Melbye M. and Hviid A. (2012) Use of calcium channel blockers and Parkinson's disease. Am. J. Epidemiol. 175, 627–635.
247. Pathak T., Agrawal T., Richhariya S., Sadaf S. and Hasan G. (2015) Store-operated calcium entry through orai is required for transcriptional maturation of the flight circuit in drosophila. J. Neurosci. 35, 13784–13799.
248. Perez-Reyes E. (2003) Molecular physiology of low-voltage-activated t-type calcium channels. Physiol. Rev. 83, 117–161.
249. Perier C., Bove J. and Vila M. (2012) Mitochondria and programmed cell death in Parkinson's disease: apoptosis and beyond. Antioxid. Redox Signal. 16, 883–895.
250. Pignatelli M. and Bonci A. (2015) Role of dopamine neurons in reward and aversion: a synaptic plasticity perspective. Neuron 86, 1145–1157.
251. Pilsl A. and Winklhofer K. F. (2012) Parkin, PINK1 and mitochondrial integrity: emerging concepts of mitochondrial dysfunction in Parkinson's disease. Acta Neuropathol. 123, 173–188.
252. Pissadaki E. K. and Bolam J. P. (2013) The energy cost of action potential propagation in dopamine neurons: clues to susceptibility in Parkinson's disease. Front Comput. Neurosci. 7, 13.
253. Platzer J., Engel J., Schrott-Fischer A., Stephan K., Bova S., Chen H., Zheng H. and Striessnig J. (2000) Congenital deafness and sinoatrial node dysfunction in mice lacking class D L-type Ca2 + channels. Cell 102, 89–97.
254. Plun-Favreau H., Klupsch K., Moisoi N. et al. (2007) The mitochondrial protease HtrA2 is regulated by Parkinson's disease-associated kinase PINK1. Nat. Cell Biol. 9, 1243–1252.
255. Poetschke C., Dragicevic E., Duda J., Benkert J., Dougalis A., DeZio R., Snutch T. P., Striessnig J. and Liss B. (2015) Compensatory T-type Ca channel activity alters D2-autoreceptor responses of Substantia nigra dopamine neurons from Cav1.3 L-type Ca channel KO mice. Sci. Rep., 5, 13688.
256. Poulin J. F., Zou J., Drouin-Ouellet J., Kim K. Y., Cicchetti F. and Awatramani R. B. (2014) Defining midbrain dopaminergic neuron diversity by single-cell gene expression profiling. Cell Rep. 9, 930–943.
257. Powers K. M., Smith-Weller T., Franklin G. M., Longstreth W. T., Jr, Swanson P. D. and Checkoway H. (2006) Diabetes, smoking, and other medical conditions in relation to Parkinson's disease risk. Parkinsonism Relat. Disord. 12, 185–189.
258. Prentice H., Modi J. P. and Wu J. Y. (2015) Mechanisms of Neuronal Protection against Excitotoxicity, Endoplasmic Reticulum Stress, and Mitochondrial Dysfunction in Stroke and Neurodegenerative Diseases. Oxid. Med. Cell Longev. 2015, 964518.
259. Proks P. and Ashcroft F. M. (2009) Modeling K(ATP) channel gating and its regulation. Prog. Biophys. Mol. Biol. 99, 7–19.
260. Puopolo M., Raviola E. and Bean B. P. (2007) Roles of subthreshold calcium current and sodium current in spontaneous firing of mouse midbrain dopamine neurons. J. Neurosci. 27, 645–656.
261. Putney J. W. (2012) Calcium signaling: deciphering the calcium-NFAT pathway. Curr. Biol. 22, R87–R89.
262. V1.3 channel voltage dependence, not Ca2 + selectivity, drives pacemaker activity and amplifies bursts in nigral dopamine neurons. J. Neurosci. 29, 15414–15419.
263. Ramanan V. K. and Saykin A. J. (2013) Pathways to neurodegeneration: mechanistic insights from GWAS in Alzheimer's disease, Parkinson's disease, and related disorders. Am. J. Neurodegener. Dis. 2, 145–175.
264. Ramirez A., Heimbach A., Grundemann J. et al. (2006) Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat. Genet. 38, 1184–1191.
265. Reeve A. K., Krishnan K. J., Elson J. L., Morris C. M., Bender A., Lightowlers R. N. and Turnbull D. M. (2008) Nature of mitochondrial DNA deletions in Substantia nigra neurons. Am. J. Hum. Genet. 82, 228–235.
266. Reeve A., Simcox E. and Turnbull D. (2014) Ageing and Parkinson's disease: why is advancing age the biggest risk factor? Ageing Res. Rev. 14, 19–30.
267. Rice M. E. and Patel J. C. (2015) Somatodendritic dopamine release: recent mechanistic insights. Philos. Trans. R. Soc. Lond. B Biol. Sci. 370, pii 20140185.
268. Rice M. E., Patel J. C. and Cragg S. J. (2011) Dopamine release in the basal ganglia. Neuroscience 198, 112–137.
269. Ritz B., Rhodes S. L., Qian L., Schernhammer E., Olsen J. H. and Friis S. (2010) L-type calcium channel blockers and Parkinson disease in Denmark. Ann. Neurol. 67, 600–606.
270. Rivas M., Villar D., Gonzalez P., Dopazo X. M., Mellstrom B. and Naranjo J. R. (2011) Building the DREAM interactome. Sci. China Life Sci. 54, 786–792.
271. Rizzuto R., Marchi S., Bonora M. et al. (2009) Ca(2 +) transfer from the ER to mitochondria: when, how and why. Biochim. Biophys. Acta 1787, 1342–1351.
272. Rodriguez M., Rodriguez-Sabate C., Morales I., Sanchez A. and Sabate M. (2015) Parkinson's disease as a result of aging. Aging Cell 14, 293–308.
273. Roeper J. (2013) Dissecting the diversity of midbrain dopamine neurons. Trends Neurosci. 36, 336–342.
274. Roselli F. and Caroni P. (2015) From intrinsic firing properties to selective neuronal vulnerability in neurodegenerative diseases. Neuron 85, 901–910.
275. Ryan B. J., Hoek S., Fon E. A. and Wade-Martins R. (2015) Mitochondrial dysfunction and mitophagy in Parkinson's: from familial to sporadic disease. Trends Biochem. Sci. 40, 200–210.
276. Salthun-Lassalle B., Hirsch E. C., Wolfart J., Ruberg M. and Michel P. P. (2004) Rescue of mesencephalic dopaminergic neurons in culture by low-level stimulation of voltage-gated sodium channels. J. Neurosci. 24, 5922–5930.
277. Samuels E. R. and Szabadi E. (2008) Functional neuroanatomy of the noradrenergic locus coeruleus: its roles in the regulation of arousal and autonomic function part I: principles of functional organisation. Curr. Neuropharmacol. 6, 235–253.
278. Sanchez-Padilla J., Guzman J. N., Ilijic E. et al. (2014) Mitochondrial oxidant stress in locus coeruleus is regulated by activity and nitric oxide synthase. Nat. Neurosci. 17, 832–840.
279. Santiago J. A. and Potashkin J. A. (2013) Shared dysregulated pathways lead to Parkinson's disease and diabetes. Trends Mol. Med. 19, 176–186.
280. Santiago J. A. and Potashkin J. A. (2014) System-based approaches to decode the molecular links in Parkinson's disease and diabetes. Neurobiol. Dis. 72 Pt A, 84–91.
281. Schapira A. H. (2008) Mitochondria in the aetiology and pathogenesis of Parkinson's disease. Lancet Neurol. 7, 97–109.
282. Schapira A. H. (2010) Complex I: inhibitors, inhibition and neurodegeneration. Exp. Neurol. 224, 331–335.
283. Schapira A. H. (2015) Glucocerebrosidase and Parkinson disease: recent advances. Mol. Cell Neurosci. 66, 37–42.
284. Schapira A. H. and Gegg M. E. (2013) Glucocerebrosidase in the pathogenesis and treatment of Parkinson disease. Proc. Natl Acad. Sci. USA 110, 3214–3215.
285. Scharinger A., Eckrich S., Vandael D. H. et al. (2015) Cell-type-specific tuning of Cav1.3 Ca(2 +)-channels by a C-terminal automodulatory domain. Front Cell Neurosci. 9, 309.
286. Schernhammer E., Hansen J., Rugbjerg K., Wermuth L. and Ritz B. (2011) Diabetes and the risk of developing Parkinson's disease in Denmark. Diabetes Care 34, 1102–1108.
287. Schiemann J., Schlaudraff F., Klose V. et al. (2012) K-ATP channels in dopamine Substantia nigra neurons control bursting and novelty-induced exploration. Nat. Neurosci. 15, 1272–1280.
288. Schlaudraff F., Grundemann J., Fauler M., Dragicevic E., Hardy J. and Liss B. (2014) Orchestrated increase of dopamine and PARK mRNAs but not miR-133b in dopamine neurons in Parkinson's disease. Neurobiol. Aging 35, 2302–2315.
289. Schondorf D. C., Aureli M., McAllister F. E. et al. (2014) iPSC-derived neurons from GBA1-associated Parkinson's disease patients show autophagic defects and impaired calcium homeostasis. Nat. Commun. 5, 4028.
290. Schultz W., Carelli R. M. and Wightman R. M. (2015) Phasic dopamine signals: from subjective reward value to formal economic utility. Curr. Opin. Behav. Sci. 5, 147–154.
291. Schwaller B. (2010) Cytosolic Ca2 + buffers. Cold Spring Harb. Perspect. Biol. 2, a004051.
292. Scigliano G., Musicco M., Soliveri P., Piccolo I., Ronchetti G. and Girotti F. (2006) Reduced risk factors for vascular disorders in Parkinson disease patients: a case-control study. Stroke 37, 1184–1188.
293. Screaton R. A., Conkright M. D., Katoh Y. et al. (2004) The CREB coactivator TORC2 functions as a calcium- and cAMP-sensitive coincidence detector. Cell 119, 61–74.
294. Seino S. (2012) Cell signalling in insulin secretion: the molecular targets of ATP, cAMP and sulfonylurea. Diabetologia 55, 2096–2108.
295. Seino S. and Miki T. (2003) Physiological and pathophysiological roles of ATP-sensitive K+ channels. Prog. Biophys. Mol. Biol. 81, 133–176.
296. Selvakumar A., Antony C., Singhal J., Tiwari B. K., Singh Y. and Natarajan K. (2014) Reciprocal regulation of reactive oxygen species and phospho-CREB regulates voltage gated calcium channel expression during mycobacterium tuberculosis infection. PLoS ONE 9, e96427.
297. Selvaraj S., Sun Y., Watt J. A., Wang S., Lei S., Birnbaumer L. and Singh B. B. (2012) Neurotoxin-induced ER stress in mouse dopaminergic neurons involves downregulation of TRPC1 and inhibition of AKT/mTOR signaling. J. Clin. Invest. 122, 1354–1367.
298. Sharma N., Crane A., Clement J. P., Gonzalez G., Babenko A. P., Bryan J., Aguilar-Bryan L. (1999) The C terminus of SUR1 is required for trafficking of KATP channels. J. Biol. Chem. 274, 20628–20632.
299. Shen K. Z. and Johnson S. W. (2010) Ca2 + influx through NMDA-gated channels activates ATP-sensitive K+ currents through a nitric oxide-cGMP pathway in subthalamic neurons. J. Neurosci. 30, 1882–1893.
300. Siebert M., Sidransky E. and Westbroek W. (2014) Glucocerebrosidase is shaking up the synucleinopathies. Brain 137, 1304–1322.
301. da Silva J. A. and Costa R. M. (2012) Bursting for exploration. Nat. Neurosci. 15, 1178–1179.
302. Simms B. A. and Zamponi G. W. (2014) Neuronal voltage-gated calcium channels: structure, function, and dysfunction. Neuron 82, 24–45.
303. Simuni T., Borushko E., Avram M. J. et al. (2010) Tolerability of isradipine in early Parkinson's disease: a pilot dose escalation study. Mov. Disord. 25, 2863–2866.
304. Singleton A. B., Farrer M. J. and Bonifati V. (2013) The genetics of Parkinson's disease: progress and therapeutic implications. Mov. Disord. 28, 14–23.
305. Sinnegger-Brauns M. J., Hetzenauer A., Huber I. G. et al. (2004) Isoform-specific regulation of mood behavior and pancreatic beta cell and cardiovascular function by L-type Ca 2 + channels. J. Clin. Invest. 113, 1430–1439.
306. Slesinger P. A., Patil N., Liao Y. J., Jan Y. N., Jan L. Y. and Cox D. R. (1996) Functional effects of the mouse weaver mutation on G protein-gated inwardly rectifying K+ channels. Neuron 16, 321–331.
307. Snutch T. P., Sutton K. G. and Zamponi G. W. (2001) Voltage-dependent calcium channels–beyond dihydropyridine antagonists. Curr. Opin. Pharmacol. 1, 11–16.
308. Sommer W. H., Costa R. M. and Hansson A. C. (2014) Dopamine systems adaptation during acquisition and consolidation of a skill. Front Integr Neurosci. 8, 87.
309. Soundarapandian M. M., Zhong X., Peng L., Wu D. and Lu Y. (2007) Role of K(ATP) channels in protection against neuronal excitatory insults. J. Neurochem. 103, 1721–1729.
310. Sours-Brothers S., Ma R. and Koulen P. (2009) Ca2 + -sensitive transcriptional regulation: direct DNA interaction by DREAM. Front Biosci (Landmark Ed) 14, 1851–1856.
311. Stocker M. (2004) Ca(2 +)-activated K+ channels: molecular determinants and function of the SK family. Nat. Rev. Neurosci. 5, 758–770.
312. Striessnig J. and Koschak A. (2008) Exploring the function and pharmacotherapeutic potential of voltage-gated Ca2 + channels with gene knockout models. Channels (Austin) 2, 233–251.
313. Striessnig J., Grabner M., Mitterdorfer J., Hering S., Sinnegger M. J. and Glossmann H. (1998) Structural basis of drug binding to L Ca2 + channels. Trends Pharmacol. Sci. 19, 108–115.
314. Striessnig J., Koschak A., Sinnegger-Brauns M. J., Hetzenauer A., Nguyen N. K., Busquet P., Pelster G. and Singewald N. (2006) Role of voltage-gated L-type Ca2 + channel isoforms for brain function. Biochem. Soc. Trans. 34, 903–909.
315. Subramaniam M., Althof D., Gispert S., Schwenk J., Auburger G., Kulik A., Fakler B. and Roeper J. (2014) Mutant alpha-synuclein enhances firing frequencies in dopamine Substantia nigra neurons by oxidative impairment of A-type potassium channels. J. Neurosci. 34, 13586–13599.
316. Sulzer D. (2007) Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease. Trends Neurosci. 30, 244–250.
317. Sulzer D. and Surmeier D. J. (2013) Neuronal vulnerability, pathogenesis, and Parkinson's disease. Mov. Disord. 28, 41–50.
318. Surmeier D. J. (2007) Calcium, ageing, and neuronal vulnerability in Parkinson's disease. Lancet Neurol 6, 933–938.
319. Surmeier D. J. and Schumacker P. T. (2013) Calcium, bioenergetics, and neuronal vulnerability in Parkinson's disease. J. Biol. Chem. 288, 10736–10741.
320. Surmeier D. J., Guzman J. N., Sanchez-Padilla J. and Goldberg J. A. (2010) What causes the death of dopaminergic neurons in Parkinson's disease? Prog. Brain Res. 183, 59–77.
321. Surmeier D. J., Guzman J. N., Sanchez-Padilla J. and Goldberg J. A. (2011) The origins of oxidant stress in Parkinson's disease and therapeutic strategies. Antioxid. Redox Signal. 14, 1289–1301.
322. Surmeier D. J., Guzman J. N., Sanchez J. and Schumacker P. T. (2012) Physiological phenotype and vulnerability in Parkinson's disease. Cold Spring Harb. Perspect Med. 2, a009290.
323. Swaab D. F., Dubelaar E. J., Hofman M. A., Scherder E. J., van Someren E. J. and Verwer R. W. (2002) Brain aging and Alzheimer's disease; use it or lose it. Prog. Brain Res. 138, 343–373.
324. Tan Y. L., Genereux J. C., Pankow S., Aerts J. M., Yates J. R., 3rd and Kelly J. W. (2014) ERdj3 is an endoplasmic reticulum degradation factor for mutant glucocerebrosidase variants linked to Gaucher's disease. Chem. Biol. 21, 967–976.
325. Tong Y. and Shen J. (2012) Genetic analysis of Parkinson's disease-linked leucine-rich repeat kinase 2. Biochem. Soc. Trans. 40, 1042–1046.
326. Tong Y., Pisani A., Martella G., Karouani M., Yamaguchi H., Pothos E. N. and Shen J. (2009) R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice. Proc. Natl Acad. Sci. USA 106, 14622–14627.
327. Toulorge D., Guerreiro S., Hirsch E. C. and Michel P. P. (2010) KATP channel blockade protects midbrain dopamine neurons by repressing a glia-to-neuron signaling cascade that ultimately disrupts mitochondrial calcium homeostasis. J. Neurochem. 114, 553–564.
328. Toulorge D., Guerreiro S., Hild A., Maskos U., Hirsch E. C. and Michel P. P. (2011) Neuroprotection of midbrain dopamine neurons by nicotine is gated by cytoplasmic Ca2 +. FASEB J. 25, 2563–2573.
329. Tovar S., Paeger L., Hess S. et al. (2013) K(ATP)-channel-dependent regulation of catecholaminergic neurons controls BAT sympathetic nerve activity and energy homeostasis. Cell Metab. 18, 445–455.
330. Traaseth N., Elfering S., Solien J., Haynes V. and Giulivi C. (2004) Role of calcium signaling in the activation of mitochondrial nitric oxide synthase and citric acid cycle. Biochim. Biophys. Acta 1658, 64–71.
331. Tucker S. J., Gribble F. M., Zhao C., Trapp S. and Ashcroft F. M. (1997) Truncation of Kir6.2 produces ATP-sensitive K+ channels in the absence of the sulphonylurea receptor. Nature 387, 179–183.
332. Turner R. W. and Zamponi G. W. (2014) T-type channels buddy up. Pflugers Arch. 466, 661–675.
333. Ungless M. A. and Grace A. A. (2012) Are you or aren't you? Challenges associated with physiologically identifying dopamine neurons. Trends Neurosci. 35, 422–430.
334. Valente E. M., Abou-Sleiman P. M., Caputo V. et al. (2004) Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304, 1158–1160.
335. Valenzuela M. J., Matthews F. E., Brayne C. et al. (2012) Multiple biological pathways link cognitive lifestyle to protection from dementia. Biol. Psychiatry 71, 783–791.
336. Van Laar V. S., Roy N., Liu A., Rajprohat S., Arnold B., Dukes A. A., Holbein C. D. and Berman S. B. (2015) Glutamate excitotoxicity in neurons triggers mitochondrial and endoplasmic reticulum accumulation of Parkin, and in the presence of N-acetyl cysteine, mitophagy. Neurobiol. Dis. 74, 180–193.
337. Verkhratsky A. (2005) Physiology and pathophysiology of the calcium store in the endoplasmic reticulum of neurons. Physiol. Rev. 85, 201–279.
338. Vila M., Ramonet D. and Perier C. (2008) Mitochondrial alterations in Parkinson's disease: new clues. J. Neurochem. 107, 317–328.
339. Virgili N., Mancera P., Wappenhans B., Sorrosal G., Biber K., Pugliese M. and Espinosa-Parrilla J. F. (2013) K(ATP) channel opener diazoxide prevents neurodegeneration: a new mechanism of action via antioxidative pathway activation. PLoS ONE 8, e75189.
340. Volman S. F., Lammel S., Margolis E. B., Kim Y., Richard J. M., Roitman M. F. and Lobo M. K. (2013) New insights into the specificity and plasticity of reward and aversion encoding in the mesolimbic system. J. Neurosci. 33, 17569–17576.
341. Wahlqvist M. L., Lee M. S., Hsu C. C., Chuang S. Y., Lee J. T. and Tsai H. N. (2012) Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson's disease occurring with Type 2 diabetes in a Taiwanese population cohort. Parkinsonism Relat. Disord. 18, 753–758.
342. Waldeck-Weiermair M., Jean-Quartier C., Rost R., Khan M. J., Vishnu N., Bondarenko A. I., Imamura H., Malli R. and Graier W. F. (2011) Leucine zipper EF hand-containing transmembrane protein 1 (Letm1) and uncoupling proteins 2 and 3 (UCP2/3) contribute to two distinct mitochondrial Ca2 + uptake pathways. J. Biol. Chem. 286, 28444–28455.
343. Wang X. and Schwarz T. L. (2009) The mechanism of Ca2 + -dependent regulation of kinesin-mediated mitochondrial motility. Cell 136, 163–174.
344. Wang Y., Qu L., Wang X. L., Gao L., Li Z. Z., Gao G. D. and Yang Q. (2015) Firing pattern modulation through SK channel current increase underlies neuronal survival in an organotypic slice model of Parkinson's disease. Mol. Neurobiol. 51, 424–436.
345. Watabe-Uchida M., Zhu L., Ogawa S. K., Vamanrao A. and Uchida N. (2012) Whole-brain mapping of direct inputs to midbrain dopamine neurons. Neuron 74, 858–873.
346. Weiser T. (2008) Ambroxol: a CNS drug? CNS Neurosci. Ther. 14, 17–24.
347. Westbroek W., Gustafson A. M. and Sidransky E. (2011) Exploring the link between glucocerebrosidase mutations and parkinsonism. Trends Mol. Med. 17, 485–493.
348. de Wet H. and Proks P. (2015) Molecular action of sulphonylureas on KATP channels: a real partnership between drugs and nucleotides. Biochem. Soc. Trans. 43, 901–907.
349. Wilson C. J. and Callaway J. C. (2000) Coupled oscillator model of the dopaminergic neuron of the Substantia nigra. J. Neurophysiol. 83, 3084–3100.
350. Winklhofer K. F. and Haass C. (2010) Mitochondrial dysfunction in Parkinson's disease. Biochim. Biophys. Acta 1802, 29–44.
351. Wise R. A. (2009) Roles for nigrostriatal–not just mesocorticolimbic–dopamine in reward and addiction. Trends Neurosci. 32, 517–524.
352. Wolfart J. and Roeper J. (2002) Selective coupling of T-type calcium channels to SK potassium channels prevents intrinsic bursting in dopaminergic midbrain neurons. J. Neurosci. 22, 3404–3413.
353. Wolfart J., Neuhoff H., Franz O. and Roeper J. (2001) Differential expression of the small-conductance, calcium-activated potassium channel SK3 is critical for pacemaker control in dopaminergic midbrain neurons. J. Neurosci. 21, 3443–3456.
354. Xu H. and Ren D. (2015) Lysosomal physiology. Annu. Rev. Physiol. 77, 57–80.
355. Yamada K. and Inagaki N. (2005) Neuroprotection by KATP channels. J. Mol. Cell. Cardiol. 38, 945–949.
356. Yamada T., McGeer P. L., Baimbridge K. G. and McGeer E. G. (1990) Relative sparing in Parkinson's disease of Substantia nigra dopamine neurons containing calbindin-D28K. Brain Res. 526, 303–307.
357. Yang F., Feng L., Zheng F., Johnson S. W., Du J., Shen L., Wu C. P. and Lu B. (2001) GDNF acutely modulates excitability and A-type K(+) channels in midbrain dopaminergic neurons. Nat. Neurosci. 4, 1071–1078.
358. Youle R. J. and van der Bliek A. M. (2012) Mitochondrial fission, fusion, and stress. Science 337, 1062–1065.
359. Zaghloul K. A., Blanco J. A., Weidemann C. T., McGill K., Jaggi J. L., Baltuch G. H. and Kahana M. J. (2009) Human Substantia nigra neurons encode unexpected financial rewards. Science 323, 1496–1499.
360. Zamponi G. W., Striessnig J., Koschak A. and Dolphin A. C. (2015) The Physiology, Pathology, and Pharmacology of Voltage-Gated Calcium Channels and Their Future Therapeutic Potential. Pharmacol. Rev. 67, 821–870.
361. Zarow C., Lyness S. A., Mortimer J. A. and Chui H. C. (2003) Neuronal loss is greater in the locus coeruleus than nucleus basalis and Substantia nigra in Alzheimer and Parkinson diseases. Arch. Neurol. 60, 337–341.
362. Zhang P. and Tian B. (2014) Metabolic Syndrome: an Important Risk Factor for Parkinson's Disease. Oxid. Med. Cell Longev. 2014, 729194.
363. Zucca F. A., Segura-Aguilar J., Ferrari E., Munoz P., Paris I., Sulzer D., Sarna T., Casella L. and Zecca L. (2015) Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease. Prog. Neurobiol. pii: S0301-0082(15)00101-X
364. Zuhlke R. D., Pitt G. S., Deisseroth K., Tsien R. W. and Reuter H. (1999) Calmodulin supports both inactivation and facilitation of L-type calcium channels. Nature 399, 159–162.